Cáncer de cavum. Experiencia institucional
DOI:
https://doi.org/10.56969/oc.v23i1.66Palabras clave:
carcinoma nasofaríngeo, virus Epstein Barr, cáncer de cabeza y cuello, nasopharyngeal neoplasms, Epstein Barr virus, head and neck cancerResumen
Los carcinomas epidermoides de cabeza y cuello son un grupo poco frecuente de neoplasias, en los Estados Unidos representan aproximadamente el 3% de todos los tumores.
El cáncer de cavum se diferencia de otros tumores de cabeza y cuello por su epidemiología, histología, historia natural y respuesta al tratamiento.
Presenta una marcada variación geográfica debido a su etiología multifactorial.
En las áreas endémicas, la incidencia y la mortalidad han disminuido en los últimos 30 años. Esto probablemente se deba a cambios en el estilo de vida y avances en la radioterapia (RT) y quimioterapia (QT) sistémica.
Citas
Siegel R, Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017; 67:7-30. DOI: https://doi.org/10.3322/caac.21387
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136:E359-86. DOI: https://doi.org/10.1002/ijc.29210
Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006; 15:1765-77. DOI: https://doi.org/10.1158/1055-9965.EPI-06-0353
Lee AW, Foo W, Mang O, et al. Changing epidemiology of nasopharyngeal carcinoma in Hong Kong over a 20-year period (1980-99): an encouraging reduction in both incidence and mortality. Int J Cancer 2003; 103:680-5. DOI: https://doi.org/10.1002/ijc.10894
Yu MC, Yuan JM. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 2002; 12:421-9. DOI: https://doi.org/10.1016/S1044579X02000858
Vaughan TL, Shapiro JA, Burt RD, et al. Nasopharyngeal cancer in a low-risk population: defining risk factors by histological type. Cancer Epidemiol Biomarkers Prev 1996; 5:587-93.
Raghupathy R, Hui EP, Chan AT. Epstein-Barr virus as a paradigm in nasopharyngeal cancer: from lab to clinic. Am Soc Clin Oncol Educ Book 2014:149-53. DOI: https://doi.org/10.14694/EdBook_AM.2014.34.149
Barnes L, Eveson JW, Reichart P, Sidransky D (eds). Pathology and genetics of head and neck tumors. World Health Organization Classification of Tumours, 2005. Lyon: International Agency for Research on Cancer.
Müller E, Beleites E. The basaloid squamous cell carcinoma of the nasopharynx. Rhinology 2000; 38:208-11.
Blanchard P, Lee A, Marguet S, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol 2015; 16:645-55. DOI: https://doi.org/10.1016/S1470-2045(15)70126-9
Ribassin-Majed L, Marguet S, Lee AWM, et al. What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol 2017; 35:498-505. DOI: https://doi.org/10.1200/JCO.2016.67.4119
Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16:1310-7. DOI: https://doi.org/10.1200/JCO.1998.16.4.1310
Rossi A, Molinari R, Boracchi P, et al. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J Clin Oncol 1988; 6:1401-10. DOI: https://doi.org/10.1200/JCO.1988.6.9.1401
Chi KH, Chang YC, Guo WY, et al. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 2002; 52:1238-44. DOI: https://doi.org/10.1016/S0360-3016(01)02781-X
Chen L, Hu CS, Chen XZ, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 2012; 13:163-71. DOI: https://doi.org/10.1016/S1470-2045(11)70320-5
Chen L, Hu CS, Chen XZ, et al. Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial. Eur J Cancer 2017; 75:150-8. DOI: https://doi.org/10.1016/j.ejca.2017.01.002
Lee AW, Tung SY, Chua DT, et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2010; 102:1188-98. DOI: https://doi.org/10.1093/jnci/djq258
Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol 2016; 17:1509-20. DOI: https://doi.org/10.1016/S1470-2045(16)30410-7
Cao SM, Yang Q, Guo L, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial. Eur J Cancer 2017; 75:14-23. DOI: https://doi.org/10.1016/j.ejca.2016.12.039
Hui EP, Ma BB, Chan KC, et al. Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma. Cancer 2015; 121:2720-9. DOI: https://doi.org/10.1002/cncr.29413
Chan ATC, Hui EP, Ngan RKC, Hui PE, et al. A multicenter randomized controlled trial of adjuvant chemotherapy in nasopharyngeal carcinoma with residual plasma EBV DNA following primary radiotherapy or chemoradiatherapy. ASCO Metting Library. En: https://meetinglibrary.asco.org/ record/69618/abstract; consultado el 3/7/2017.
Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. Lancet 2016; 387:1012-24. DOI: https://doi.org/10.1016/S0140-6736(15)00055-0
Descargas
Publicado
Cómo citar
Número
Sección
Categorías
Licencia
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
